The FDA launches a new rare disease development initiative, BioNTech’s BNT113 misses a progression-free survival endpoint, and Viking Therapeutics begins Phase III trials of its oral obesity candidate.
|Articles|January 9, 2008
Bush Signs Bill Providing FDA $1.73 Billion for Fiscal 2008
Author(s)BioPharm International Editors
On December 26, 2007, President Bush signed into law H.R. 2764, which gives the FDA nearly $1.73 billion in funding for fiscal 2008.
Advertisement
On December 26, 2007, President Bush signed into law H.R. 2764, which gives the FDA nearly $1.73 billion in funding for fiscal 2008.
As reported by FDA News, the bill gives the FDA more than $79 million above the president’s budget request and $145 million above the fiscal 2007 funding level. The Center for Drug Evaluation and Research (CDER) will receive more than $682 million, with $41.9 million of that going to the Office of Generic Drugs. The Center for Biologics Evaluation and Research (CBER) will receive more than $236 million.
Details on the bill can be seen at
Advertisement
Related to this article
As ArsenalBio, TScan, Bristol Myers Squibb, and others abandon ex vivo programs for in vivo engineering, early clinical data and platform differences point to both the promise and the unresolved safety, manufacturing, and regulatory questions of generating CAR-T cells inside the body.
FDA’s rare disease framework effort will revisit evidence expectations and manufacturing review, with public input starting Oct. 28.
BNT113 plus pembrolizumab failed to significantly extend progression-free survival in a 285-patient HPV16-positive head and neck cancer trial.
Viking Therapeutics has started two Phase 3 trials of once-daily oral VK2735, a dual GLP-1/GIP receptor agonist, in adults with obesity, with and without type 2 diabetes.
Gilead will develop up to three PRO-XTEN T-cell engagers discovered by Vir Biotechnology for solid tumors in a deal worth up to $1.74 billion.
The FDA has accepted Pierre Fabre Pharmaceuticals’ resubmitted BLA for tabelecleucel, an allogeneic T-cell immunotherapy for EBV+ post-transplant lymphoproliferative disease. The FDA’s target action date is March 31, 2027.
FDA reviews a proposed Keytruda biosimilar, Roche expands its obesity pipeline with an RNAi deal, and guselkumab shows promise for fistula remission in Crohn disease.
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
BioNTech's BNT113 Misses PFS Goal in Head and Neck Cancer Trial
4
Gilead Taps Vir Biotechnology's PRO-XTEN Tech for Solid Tumors
5